## CLAIMS

1. An allogeneic composition comprising Vδ1+ T cells for use in the treatment of a patient with a myeloid malignancy.

2. The allogeneic composition for use as defined in claim 1, wherein the myeloid malignancy is selected from acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS).

3. The allogeneic composition for use as defined in claim 1 or claim 2, wherein the patient is positive for minimal residual disease (MRD+).

4. The allogeneic composition for use as defined in claim 3, wherein the MRD+ patient is in complete remission, contains no detectable leukaemic blasts in the peripheral blood and contains less than 5% leukaemic blasts in the bone marrow.

5. The allogeneic composition for use as defined in any one of claims 1 to 4, wherein the patient has previously been treated with chemotherapy.

6. The allogeneic composition for use as defined in claim 5, wherein the patient has been treated with chemotherapy at least 3 days prior to administration of the allogeneic composition.

7. The allogeneic composition for use as defined in claim 5 or claim 6, wherein the chemotherapy is selected from fludarabine and cyclophosphamide.

8. The allogeneic composition for use as defined in any one of claims 1 to 7, which comprises at least about 90% CD45+ cells relative to total live cells.

9. The allogeneic composition for use as defined in any one of claims 1 to 8, which comprises at least about 60% γδ T cells relative to total live cells.

10. The allogeneic composition for use as defined in any one of claims 1 to 9, which comprises at least about 50% Vδ1+ T cells relative to total live cells.

11. The allogeneic composition for use as defined in any one of claims 1 to 10, which comprises less than about $1 \times 10^{10}$ total live cells.

12. The allogeneic composition for use as defined in claim 11, which comprises less than about $1 \times 10^{9}$ total live cells.

13. The allogeneic composition for use as defined in claim 12, which comprises less than about 1 x $10^8$ total live cells.

14. The allogeneic composition for use as defined in any one of claims 1 to 11, wherein the allogeneic composition comprises about 8 x $10^9$, 4 x $10^9$, 2.4 x $10^9$, 1.2 x $10^9$, 8 x $10^8$, 4 x $10^8$, 8 x $10^7$ or 4 x $10^7$ total live cells.

15. A dose comprising the allogeneic composition for use as defined in any one of claims 1 to 14.

16. The dose as defined in claim 15, which comprises less than about 1 x $10^5$ cells/kg.

17. The dose as defined in claim 15, which comprises less than about 1 x $10^6$ cells/kg.

18. The dose as defined in claim 15, which comprises less than about 1 x $10^7$ cells/kg.

19. The dose as defined in claim 15, which comprises less than about 3 x $10^7$ cells/kg.

20. The dose as defined in claim 15, which comprises less than about 1 x $10^8$ cells/kg.

21. The dose as defined in claim 15, which comprises less than about 5 x $10^4$ αβ T cells/kg.

22. The dose as defined in claim 21, which comprises less than about 1 x $10^4$ αβ T cells/kg.

23. The allogeneic composition for use as defined in any one of claims 1 to 15, wherein the Vδ1+ T cells are obtained from a sample by a method comprising culturing the sample in a medium comprising a T cell mitogen and a growth factor having interleukin-4-like activity, in the absence of a growth factor having interleukin-15-like activity.

24. The allogeneic composition for use as defined in any one of claims 1 to 15, wherein the Vδ1+ T cells are obtained from a sample by a method comprising culturing the sample in a medium comprising a T cell mitogen and a growth factor having interleukin-15-like activity, in the absence of a growth factor having interleukin-4-like activity.

25. The allogeneic composition for use as defined in claim 23 or claim 24, wherein the Vδ1+ T cells are collected after at least 11 days of culturing.

26. The allogeneic composition for use as defined in any one of claims 23 to 25, wherein the culturing is performed in a vessel comprising a gas permeable material.

27. The allogeneic composition for use as defined in claim 26, wherein the vessel comprises a liquid sealed container comprising a gas permeable material to allow gas exchange.

28. The allogeneic composition for use as defined in claim 26 or claim 27, wherein the bottom of said vessel is configured to allow gas exchange from the bottom of the vessel.

29. The allogeneic composition for use as defined in any one of claims 23 to 28, wherein the sample is cultured in serum-free medium.

30. The allogeneic composition for use as defined in any one of claims 23 to 28, wherein the sample is cultured in media containing serum or serum-replacement.

31. A method of treating a myeloid malignancy comprising administering a therapeutically effective amount of an allogeneic composition comprising Vδ1+ T cells to a patient with said myeloid malignancy.

32. The method as defined in claim 31, wherein the myeloid malignancy is selected from AML and MDS.

33. The method as defined in claim 31 or claim 32, wherein the patient is positive for minimal residual disease (MRD+).

34. The method as defined in claim 33, wherein the MRD+ patient is in complete remission, contains no detectable leukaemic blasts in the peripheral blood and contains less than 5% leukaemic blasts in the bone marrow.

35. The method as defined in any one of claims 31 to 34, which additionally comprises administration of chemotherapy.

36. The method as defined in claim 35, wherein the patient is treated with chemotherapy at least 3 days prior to administration of the allogeneic composition.

37. The method as defined in claim 35 or claim 36, wherein the chemotherapy is selected from fludarabine and cyclophosphamide.

38. The method as defined in claim 31, wherein the therapeutically effective amount comprises about $8 \times 10^9$, $4 \times 10^9$, $2.4 \times 10^9$, $1.2 \times 10^9$, $8 \times 10^8$, $4 \times 10^8$, $8 \times 10^7$ or $4 \times 10^7$ total live cells.

39. The method as defined in claim 31, wherein the therapeutically effective amount comprises less than about $1 \times 10^{10}$ total live cells.

40. The method as defined in claim 31, wherein the therapeutically effective amount comprises less than about $1 \times 10^9$ total live cells.

41. The method as defined in claim 31, wherein the therapeutically effective amount comprises less than about $1 \times 10^8$ total live cells.

42. The method as defined in claim 31, wherein the therapeutically effective amount comprises less than about $5 \times 10^4$ αβ T cells/kg.

43. The dose as defined in claim 42, wherein the therapeutically effective amount comprises less than about $1 \times 10^4$ αβ T cells/kg.